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Consumption of the isoﬂavones daidzein, genistein, glycitein, and their structural analogues is generally considered beneﬁcial to
human health. Equol is not found in soy, but is converted from daidzein by human gut bacterial ﬂora. Research indicates that
between 30–50% of the population is capable of converting daidzein to equol; therefore, there has been recent development of
a new equol-rich functional food that relies on bacterial conversion of daidzein to equol under strictly controlled conditions.
Therefore, a new equol-rich soy product (SE5-OH) has been developed, based on the bacterial conversion of daidzein; and
its reproductive and developmental toxicity has been evaluated in a two-generation study and a developmental toxicity study
with Sprague-Dawley rats at dose levels of 200, 1000, and 2000mg/kg/day by gavage. SE5-OH contains approximately 0.65%
equol, 0.024% daidzein, 0.022% genistein, and 0.30% glycitein. From the reproductive study, the no-observed-adverse-eﬀect-level
(NOAEL) for SE5-OH determined for both male and female rats is 1000mg/kg/day (6.5mg equol/kg/day). In the developmental
toxicity phase of the study, no eﬀects by SE5-OH were found in the embryo-fetus at any of the doses tested. The NOAEL for
developmental eﬀects of SE5-OH is 2000mg/kg/day (13mg equol/kg/day).
Copyright © 2009 Ray A. Matulka et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Over the past two decades, scientiﬁc literature has indi-
cated that consumption of soy products and, in particular,
their isoﬂavone components have been associated with the
reduction of the risk of cancer, coronary vascular disease,
osteoporosis, and other pathologies that are associated with
menopause and ageing in both sexes [1–3]. One such
isoﬂavoneisequol:amicrobialmetaboliteofdaidzein,which
is structurally related to 17β-estradiol [4]. Consumption of
daidzein in subjects that were found to be able to metabolize
daidzein to equol has been linked with delay in the onset of
menopause and menopausal-associated symptoms, markers
ofcardiovasculardisease,andprostatecancer[5,6];however,
there is conﬂicting evidence concerning the ability to pro-
duce equol and subsequent health beneﬁts [6, 7]. Although
there are known dietary sources of equol, the levels of equol
in these milk samples are relatively low (in the range of
60–450ngequol/mL) [8, 9]. Therefore, the consumption of
equol-enriched soy-based products may be of health beneﬁt
to individuals who do not convert daidzein to equol.
In nature, equol is formed exclusively by the intestinal
microbiota although chemical synthesis pathways have also
been described [10, 11]. The enzymatic process of producing
equol from daidzein resides with the gut microbial ﬂora [12,
13], similar to the pathway presented in Figure 1. Although
it has been estimated that there are more than 400 species
of bacteria in the human gut that may inﬂuence the normal
structure and function of the intestinal system [14, 15],
research indicates that, depending upon the population
studied, between 30–50% of the population is host to
bacteria which metabolize daidzein into equol [6, 16, 17].
Recentresearchhasindicatedthathumansthathostbacteria,
able to metabolize daidzein to equol, convert approximately
30–40% of daidzein into equol, and the types of food
consumed may be one of several factors that aﬀect the ability2 Journal of Toxicology
Table 1: Isoﬂavone constituents of SE5-OH.
Isoﬂavone ingredient
∗ Reproductive toxicity study (Lot 060106P)
∗∗ (mg/g) Reproductive toxicity study and developmental
toxicity study (Lot 051206P)
∗∗ (mg/g)
∗
Daidzein 0.323 ±0.0015 0.275 ±0.0025
Genistein 0.293 ±0.0017 0.287 ±0.0032
Glycitein 1.65 ±0.015 2.04 ±0.010
Dihydrodaidzein 0.362 ±0.0021 0.337 ±0.0036
Equol 5.16 ±0.070 5.24 ±0.025
∗The amount of each isoﬂavone ingredient is the average of three separate measurements, mean ± standard deviation.
∗∗Both lots were used in the reproductive study, while only Lot 051206P was used in the developmental study.
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Figure 1: Daidzein metabolism to equol.
to produce equol [18–20]. Serum levels of equol in equol
producers that consume daidzein have been noted at up to
76 ±137nmol/L.
The content of equol in the soy-based product (SE5-
OH) has been enriched as a result of fermentation of soy
germ with the bacterium L. garvieae (Otsuka Pharmaceutical
Co., Ltd., Chiyoda-ku, Tokyo, Japan). L. garvieae is not a
normal member of the human gut ﬂora, but is typically
found in ﬁsh, and within ﬁsh aquacultures, and is associated
with decreased growth rates, an unmarketable appearance,
and mortality, but is not known to produce toxins [21].
L. garvieae is a rare pathogen with a low virulence in humans
with gastrointestinal disorders that consumed raw ﬁsh, also
has been found in several diﬀerent cheeses, and may be
an important fermentation microbe in the production of
several cheeses, including artisanal Italian and traditional
Egyptian Domiati cheeses [22–25]. The controlled process
of soy fermentation with L. garvieae is capable of converting
approximately 50% of the daidzein contained within the
soy to equol. SE5-OH is autoclaved to kill the bacteria,
and subsequently analyzed to ensure that SE5-OH does not
contain any living L. garvieae; therefore, the live organism
will not be ingested by the consumer.
Previously, we have reported acute and subchronic toxic-
itystudiesofSE5-OHintheadultratmodel,anddetermined
the NOAEL to be 2000mg/kg/day following administration
for 90 days [26]. The objective of the studies described
herein was to investigate the eﬀect of the speciﬁc equol-
enriched soy-based SE5-OH product on rat development
and reproduction over two generations.
2.Methods and Materials
2.1. Test Articles. The test article, referred to as SE5-OH,
was prepared by a controlled fermentation of a daidzein-
richsoygermcontainingisoﬂavoneswithL.garvieae(Otsuka
Pharmaceutical Co., Ltd., Chiyoda-ku, Tokyo, Japan). SE5-
OH contains approximately 0.65% equol, 0.024% daidzein,
0.022% genistein, and 0.30% glycitein. The test article is a
light brown powder that includes ﬁve speciﬁc isoﬂavones;
the amounts in the two lots of test article used in these
studies are presented in Table 1. The test article control was
hydroxypropylmethylcellulose (HPMC), supplied by Shin-
Etsu Chemical Co., Ltd (Chiyoda-ku, Tokyo, Japan).
2.2. Animals. Male and/or female Crl:CD(SD) rats, supplied
by the Atsugi Breeding Center of Charles River Laboratories
(CRL) Japan, Inc., (Kohoku-ku, Yokohama, Japan) were
used for both the developmental and reproductive toxicity
studies. All animals were clinically monitored at the time
of delivery to the testing facility and during the acclimation
period. Housing consisted of stainless steel or polycarbonate
cages,withatwelve-hourlightperiod(7:00 AMto7:00 PM).
Temperature was maintained at 20.1–23.4
◦Cw i t har e l a t i v e
humidity of 49.6–69.2% and 6–20 air changes/h. The
bedding, which was used only in the reproductive toxicity
study, was of the Beta-Chip brand supplied by Charles River
Laboratories Japan, Inc. The rats were six weeks of age at the
start of dosing in the reproductive toxicity study and twelve
weeks of age at mating in the developmental toxicity study.
Rats were acclimatized for ﬁve or six days before use.
2.3. Guidelines. The developmental toxicity and
reproductive toxicity studies were carried out under the
guidelines of Redbook 2000 and FDA’s Toxicological Principles
for the Safety Assessment of Food Ingredients [27, 28]. Both
studies were conducted within the Good Laboratory Practice
(GLP) standards for the conduction of nonclinical studies
on the safety of drugs (Ministry of Health and Welfare
(MHW), Japan, Ordinance Number 21, 26 March 1997,
[http://pdg-a258.koyosha.co.jp/jsqa2/en/glp/glp424e.html]).
This study was approved by the Committee of KashimaJournal of Toxicology 3
Laboratory for Ethics in Animal Studies in compliance
with “Guidelines for Animals Studies (Kashima Laboratory,
Mitsubishi Chemical Safety Institute Ltd., Kamisu-shi,
Ibaraki, Japan).”
2.4. Experimental Design
2.4.1. Developmental Toxicity Study
(1) Exposure and Observations. On gestational days (GDs)
6–19, three groups of 22 pregnant females were administered
doses of SE5-OH in 1% aqueous HPMC by gavage at levels
of 200, 1000, and 2000mg/kg/day, respectively; the control
group (22 pregnant females) was administered 1% HPMC
vehicle only. Animals were observed twice daily for clinical
signs during the dosing period, and once daily following the
dosing regimen. Body weights and gross weights of the diets
were measured on GD 0, 6, 8, 10, 12, 14, 16, 18, and 20.
Body weight gain was calculated on the basis of body weights
measured on GD 6.
(2) Necropsy. On GD 20, dams were euthanized, the gravid
uterus was collected from each dam and weighed to allow
for calculation of corrected body weight and corrected
body weight gain. Corrected body weight was determined
by subtracting the gravid uterine weight from the body
weight on GD 20, while the corrected body weight gain was
calculated by subtracting the body weight on GD 6 from the
corrected body weight. At necropsy of the dams, thoracic
and abdominal organs and tissues were examined macro-
scopically. Any organs or tissues showing abnormalities were
collected and preserved. If such collections were conducted,
the same tissues were collected from three control dams
and also preserved. Ovaries and uterus were removed and
examined for the number of corpora lutea, implantations,
live fetuses, and dead embryos. Early embryonic deaths were
considered to be represented by the number of implantation
sites plus placental remnants; late embryonic deaths were
represented by macerated embryos plus dead fetuses.
Live fetuses were weighed, euthanized, sexed, and exam-
ined (external and oral cavity examinations). Approximately
half of the live fetuses in each litter from the control
and the 2000mg/kg dose dams were subjected to visceral
examination, which included the head, neck, thorax, and
abdomen. The remaining fetuses were examined for skeletal
anomalies and degrees of ossiﬁcation in cervical vertebral
bodies, sternebrae, metacarpi, metatarsi, and sacral/caudal
vertebral bodies.
2.4.2. Reproductive Toxicity Study. Groups of 52 rats (26/sex/
group) served as the F0 generation and were administered
the same SE5-OH test article at the same doses via gavage
as in the developmental toxicity study (i.e., 0, 200, 1000,
and2000mg/kg/day).Dosingcommencedatsixweeksofage
and lasted for ten weeks before mating and then throughout
the mating period. The mating procedure involved the
placement of one male and one female in the same cage
for a maximum of two weeks, with reproductive capacity
judged by copulation index, fertility index, precoital period,
gestationperiod,andgestationindex.F0 femalesthatbecame
pregnant continued on this exposure regimen through
gestation and lactation until weaning of the F1 animals. The
F1 generation males and females were also administered the
same dosing regimen of SE5-OH, beginning on postnatal
day (PND) 21, for ten to eleven weeks before mating
and throughout the mating period, with pregnant females
continuing on the dosing schedules through gestation and
lactation until weaning of the F2 generation. Throughout
this entire process, animals were observed twice daily for
clinical signs; body weights and food consumption were
measured weekly until the start of gestation in both F0 and
F1 generations. Estrous cycle was examined for three weeks
before the start of mating in both F0 and F1 females. During
gestation, females in both generations were weighed on GD
0, 3, 7, 10, 14, 17, and 20 and then on lactation day (LD) 0,
4, 7, 10, 14, 17, and 21 during lactation. Food consumption
was also measured during GD 0, 7, 14, and 20 and on LD 0,
4, 7, 14, and 21. On the day after the animals reached the end
of their respective exposure periods, they were euthanized
for gross necropsy. The following tissues were weighed
and preserved: adrenals, brain, kidney, liver, female repro-
ductive tissues (uterus, ovaries), male reproductive tissues
(testes, epididymis, prostate, and seminal vesicles including
coagulating glands), pituitary, spleen, thymus (neonatal
only), and thyroid gland. Histological examinations were
conducted on tissues from control and high- (2000mg/kg)
dose groups only and included adrenals (F0 females were
examined in all dose groups), male and female reproductive
organs, pituitary, and liver tissues from F0 females. Sperm
was also collected from the cauda epididymis of all F0
and F1 males and evaluated for motility, and the sperm
from the control and 2000mg/kg dose group were also
evaluated for spermatid cells (testis), sperm number, and
morphology.
Clinical parameters for oﬀspring included examination
for external anomalies, sex ratios, live birth index (i.e.,
number of live pups/number of total pups born), as well
as viability index on PND 4 and weaning index on PND
21; pup weights were measured at birth as well as PND
4, 7, 14, and 21. On PND 4, litter sizes were adjusted
randomly to eight pups per dam. Pups were also examined
forphysicalandfunctionaldevelopmentalparameters,which
included incisor eruption, eye opening, reﬂexes for righting,
auditory startle, pain, corneal, and pupillary reactions.
Sexual maturation was determined in F1 rats by recording
the age and weight on the day of vaginal opening after
PND 27 was reached or when balanopreputial separation
from PND 35 was recorded. At gross necropsy of F1 and
F2 weanlings, brain, spleen, and thymus were collected from
selected animals for preservation (one male and one female
selected from each litter in numerical order of the oﬀspring
number in each litter, which was randomly assigned).
Ovaries, vagina, and uterus were collected from females,
while testes, epididymis, seminal vesicles, and prostate were
collected from males. Organ weights were determined from
one animal of each sex per litter for brain, thymus, spleen,
and uterus.4 Journal of Toxicology
2.5. Statistical Analyses. Statistical analysis for the repro-
ductive and developmental toxicity study was conducted
using several diﬀerent tests, using the toxicological data
processing system (MiTOX, Mitsui Zosen Systems Research,
Inc., Japan). The data of oﬀspring obtained before weaning
were analyzed on the basis of litter mean values except for
the sex ratio. The normality of the data was assumed, unless
otherwise indicated. Homogeneity of variance was tested by
Bartlett’s test; when the data were homogeneous, a one-way
analysis of variance (ANOVA) was performed for statistical
comparison. Heterogeneous data were tested by the Kruskal-
Wallis test. When a signiﬁcant intergroup diﬀerence was
found, Dunnett’s or the Dunnett-type multiple comparison
test was used. For some of the data (e.g., days until copula-
tion, number of estrus stages without copulation, gestation
length, sperm motility, birth index, viability index on PND
0, 4, and 21, incidence of oﬀspring with external anomalies,
postnatal physical development, reﬂex and sensory function,
as wellas sexual maturation (vaginalopening and cleavageof
balanopreputial gland)), the Kruskal-Wallis test was applied
ﬁrst, and when a signiﬁcant intergroup diﬀerence was found,
the Dunnett-type multiple comparison test was used. The
multiple comparison test was utilized to evaluate statistical
signiﬁcance of changes in body weight, body weight gain,
food consumption, organ weights, number of implantations,
number of oﬀspring, number of live oﬀspring, and estrous
cycle lengths. However, for the spermatid count and sperm
count, the homogeneity of variance was tested by the F
test, and when the variance was homogeneous, Student’s
t-test was performed for the statistical comparison. When
heterogeneous, the Aspin-Welch t-test was used. Moreover,
Wilcoxon’s rank sum test was used for comparison of the
incidence of abnormal sperm (morphologically abnormal
sperm and tailless sperm), visceral examination, and skeletal
examinations. The categorical data (e.g., copulation index,
fertility index, gestation index, sex ratio (male/female),
incidence of females with irregular estrous cycles, and dams
with external abnormal oﬀspring) were analyzed by Fisher’s
exact probability test. All statistical tests used two-tailed
signiﬁcance level of 5%.
3. Results
3.1. Developmental Toxicity Study
3.1.1. Eﬀects on Dams. With the exception of a transient lack
of weight gain (see Figure 2), no abnormal clinical signs were
observed in any of the dams. This included observations for
death, moribundity, abortion, or premature delivery (data
not shown). In dams exposed to 2000mg/kg, signiﬁcant
decreases in body weight gain were noted on GD 8–16 but
these values had returned to control levels by GD 20. The
same transient lack of weight gain was noted for dams in
the 1000mg/kg exposure group, but only on GD 8. No
treatment-related eﬀects were seen for food consumption,
gravid uterine weights, corrected body weight, and corrected
body weight gain; and there were no abnormalities seen at
necropsy (data not shown).
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Figure 2: Changes in body weight gain (grams) observed in
dams exposed to SE5-OH during gestational days 0–20 during the
developmental toxicity study in rats; signiﬁcant when compared to
control: ∗P<. 05; ∗∗P<. 01
3.1.2. Eﬀects on Embryo-Fetal Development. In all treated
groups, there were no signiﬁcant diﬀerences in number of
corpora lutea, implantations, dead embryos, postimplanta-
tion losses, live fetuses, fetal deaths, fetal weight, or sex ratio.
Several isolated embryo-fetal eﬀects were noted during the
placental observations, and external, visceral, and skeletal
examinations. These changes are summarized in Table 2.
3.2. Reproductive Toxicity Study
3.2.1. Parental Animals. Transient decrease of weight gain
and reduced food intake in the F0 and F1 females of
2000mg/kg/day, and histological change of adrenal cortex
(a diﬀuse increase in lipid droplets in the zona glomeru-
losa) in the F0 females of 2000mg/kg/day were noted
(see Table 3). Food intake was reduced in the F0 females
in the 1000mg/kg/day group. In addition, increased liver
weight in the F0 female of 1000 and 2000mg/kg/day dose
groups, increased adrenal weight in the F0 males at the
2000mg/kg/day dose group, as well as increased thyroid
weight in the F1 males (see Table 4) was noted. No adverse
clinical signs (including death, moribundity, abortion, or
premature delivery), necropsy ﬁndings, or organ weights
were observed in any of the F0 and F1 parental animals.
There were no adverse reproductive eﬀects observed in
any treatment group of F0 and F1 animals in terms of
estrous cycle, copulation index, fertility index, or precoital
period (see Tables 5 and 6). No adverse eﬀects were seen in
gestation period, gestation index, or parturition. No eﬀect
on implantation number was found in the F0 generation
although the number of implantations was slightly, but
signiﬁcantly, reduced in the F1 dams at 2000mg/kg/day,
there were no eﬀects on implantation in the 200 and
1000mg/kg/da F1 generation (see Tables 7 and 8). The
decrease in implantation number in the high dose did
not signiﬁcantly aﬀect the birth index or the number ofJournal of Toxicology 5
Table 2: Isolated embryo-fetal eﬀects noted during necropsy observations/examinations in the developmental toxicity study in rats.
Eﬀect Occurrence
Fusion of placentae
Occurred in one dam in the 200mg/kg dose group. No other
placental abnormalities identiﬁed in any group.
Rudimentary tail
Occurred in one fetus of the 1000mg/kg dose group. No other
external fetal abnormalities identiﬁed in any group.
Visceral anomaly: ventricular septal defect
Occurred in one control group fetus and one 2000mg/kg group
fetus. No other anomalies identiﬁed in any group.
Visceral variants: thymic neck remnant, supernumerary coronary
ostium, left umbilical artery, and renal pelvis dilation
Occurred with equal incidence in the control and 2000mg/kg
groups.
Skeletal anomalies/malformations: wavy and nodulated ribs
Occurred in one 2000mg/kg group fetus. No other anomalies
identiﬁed in any group.
Skeletal variants: foramen hypoglossi double, closure of transverse
foramenofoneormorecervicalvertebralarches,transverseforamen
opening in 7th cervical arch, splitting of ossiﬁcation centers in
thoracic vertebral bodies, hemicentric thoracic centrum, dumbbell
ossiﬁcation of thoracic centrum, lumbarization, cervical ribs, short
supernumerary 14th rib, reduced 13th ribs, splitting of sternebrae
Incidence of dumbbell ossiﬁcation of thoracic centrum was
signiﬁcantlylowinthe2000mg/kgdosinggroupbutwasjudged
incidental with no toxicological signiﬁcance.
oﬀspring born alive. SE5-OH administration to male rats
did not aﬀect any of the sperm parameters evaluated, which
included sperm motility, percentage and type of abnormal
sperm, tailless sperm, sperm count, or the number of
homogenization-resistant sperm (see Table 9).
3.2.2. Oﬀspring Development. Reproductive performance for
the F0 generation was initiated with 26 mating pairs. While
not statistically signiﬁcant, 2, 2, and 1 pairs in the 200,
1000, and 2000mg/kg/day dose groups, respectively, did
not copulate. In the copulating pairs, nonpregnant females
were observed in 1, 2, and 3 cases of the control, 1000,
and 2000mg/kg/day groups, respectively; again, this did not
result in a signiﬁcant diﬀerence in the fertility index. The F0
breeding resulted in 25, 24, 22, and 22 dams in the control,
200, 1000, and 2000mg/kg/day dose groups, respectively.
The number of litters delivered resulted in 24, 23, 22, and
22 litters/dose in the control, 200, 1000, and 2000mg/kg/day
dose groups, respectively (see Table 10) .O n ec o m p l e t el i t t e r
in the 1000mg/kg/day dose group was lost on PND 2.
For F1 rat pups, one male and one female were randomly
selected from each litter on PND 21 and were used as
breeding animals in the F1 generation (siblings not paired).
One male pup in the control group died on PND 21,
and one female 1000mg/kg/day pup died on PND 22. In
addition, two F1 females in the control group and one F1
male in the 1000mg/kg group that had no mating partner
were not subjected to mating. This resulted in 22, 23, 20,
and 22 breeding F1 pairs in the control, 200, 1000, and
2000mg/kg/day dose groups, respectively. All mating pairs
copulated except for one pair in each of the control and
200mg/kg/day groups. Three, 3, 1, and 1, nonpregnant
females occurred in control, 200, 1000, and 2000mg/kg/day
dose groups, respectively. One female died with vaginal
hemorrhage on GD 23 in the 200mg/kg/day dose group,
which was not considered to be test article-related. One male
of the control group could not fertilize the mating female,
and one male of the 2000mg/kg/day dose group exhibited
unilateral small and soft testis and small epididymis, and
the mated female of this male had only one implantation
with no delivery. These eﬀects were not signiﬁcant and not
considered to be related to test article administration, as
they were not dose-related responses. Of the dose groups,
18, 18, 19, and 21 F1 dams gave birth to live F2 oﬀspring
(see Table 11). There were no changes attributable to the test
articleinparturitionornursing.Totallitterlosswasobserved
foronedameachinthe200and2000mg/kg/daydosegroups
on PND 4 and PND 1, respectively; however, this was judged
to be incidental as this was not a dose-dependent eﬀect.
In the F2 generation, the number of female oﬀspring
was reduced at the 2000mg/kg/day dose on PND 4 (P<
.05), but neither the number of live oﬀspring on PND 21
nor the viability index was aﬀected. This reduction was
not caused by prenatal death or a diﬀerence in the birth
index, but was only a reﬂection of a nonsigniﬁcant reduction
in the number of implantations. The total litter loss on
PND 1 was judged to be incidental, as there was no dose
dependency in the incidence and no abnormalities in the
maternal behavior in the dams. There were no adverse eﬀects
observed in any treatment group of F1 and F2 oﬀspring:
clinical signs, body weight, external anomalies, sex ratios,
viability index, physical development, reﬂex function, organ
weight, necropsy ﬁndings, and sexual maturation (data not
shown), or viability index (see Table 11).
4. Discussion
Soy is the most widely used food plant in the world and has
been cultivated for over 4500 years, resulting in human soy
isoﬂavone consumption for several millennia [29]. Recently6 Journal of Toxicology
Table 3:BodyweightandfoodconsumptioninmaleandfemaleSprague-Dawleyratsduringthetwo-generationreproductivetoxicitystudy.
Generation F0 F1
Dose
(mg/
kg/day)
Gender Period
(days) 0 200 1000 2000 0 200 1000 2000
Body
weight (g)
Male Premating
0 195.9 ±6.6 196.5 ±5.7 196.2 ±6.3 195.5 ±
6.2 59.6 ±4.9# 59.7 ±5.05 9 .4 ±5.75 7 .1±5.1
70 540.0±47.2 560.1±56.6 534.3±46.4 539.3 ±
41.2 451.8±35.1 461.±32.1 442.8±37.8 445.5 ±
34.9
(n = 26) (n = 26) (n = 26) (n = 26) (n = 23) (n = 23) (n = 21) (n = 22)
Female Premating
0 152.2 ±8.5 152.5 ±6.9 151.0 ±6.9 151.2 ±
6.8 55.4 ±6.05 7 .0 ±5.85 7 .6 ±4.85 4 .8±5.5
70 303.9±35.6 298.3±21.5 289.2±22.4 283.0 ±
19.1
∗ 266.6±22.9 270.0±26.8 263.2±21.0 252.9 ±
17.1
(n = 26) (n = 26) (n = 26) (n = 26) (n = 24) (n = 23) (n = 20) (n = 22)
Gestation
7 337.9±28.8 333.9±21.3 323.3±22.7 318.5 ±
21
∗ 358.9±32.3 367.1±34.9 352.6±29.6 334.7 ±
20.7
∗
14 371.0±29.5 364.0±23.3 355.4±23.8 349.3 ±
23.4
∗ 395.4±34.4 400.9±35.5 383.4±29.6 367.6 ±
22.9
∗
20 443.0±36.4 440.2±25.4 434.7±26.7 428.9 ±
23.6 474.9±40.5 473.3±39.1 453.9±38.9 437.3 ±
34.9
∗∗
(n = 25) (n = 24) (n = 22) (n = 22) (n = 18) (n = 19) (n = 19) (n = 21)
Lactation 21 355.0±24.2 345.8±20.4 345.3±21.7 343.0 ±
19.5 365.3±25.6 370.8±28.0 368.0±22.8 355.8 ±
14.8
(n = 24) (n = 23) (n = 21) (n = 22) (n = 18) (n = 17) (n = 18) (n = 19)
Body
weight
gain (g)
Male Premating 0–70 344.1±45.1 363.6±54.4 338.1±43.7 343.8 ±
40.0 392.3±34.1 401.8±30.2 383.4±34.1 388.4 ±
32.1
Female Premating 0–70 151.7±31.1 145.9±20.4 138.2±19.3 131.9 ±
16.5
∗ 211.2±20.8 213.0±25.0 205.4±19.3 198.1 ±
16.9
Gestation
0–7 33.2 ±7.13 1 .3 ±5.52 9 .6 ±8.93 0 .7±7.93 6 .8 ±7.73 4 .6 ±8.73 2 .1 ±9.33 3 .3±7.9
0–14 66.3 ±12.76 1 .4 ±8.86 1 .7 ±8.0 61.5 ±
12.4 73.2 ±8.46 8 .4 ±12.16 2 .8±10.7
∗ 66.2 ±
11.8
0–20 138.3±22.3 137.6±16.4 141.0±11.0 141.0 ±
18.5 152.8±13.0 140.8±24.5 133.3 ±
20.8
∗∗
136.0 ±
26.5
Lactation 0–21 1.6 ±20.3 −2.4±20.26 .8 ±20.83 .4±13.9
−20.3 ±
20.5
−17.4 ±
25.4
−7.7 ±23.4
−5.5 ±
23.0
Food con-
sumption
(g)
Male Premating 70 26.2 ±1.92 6 .9 ±1.82 5 .4 ±1.62 5 .1±1.83 0 .5 ±2.03 1 .3 ±1.82 9 .0 ±1.82 8 .9±1.9
Female Premating 70 19.0 ±1.71 8 .5 ±1.61 7 .6 ±1.2
∗ 16.3 ±
0.9
∗∗ 20.3 ±2.12 0 .6 ±1.51 9 .2 ±1.3 17.5 ±
1.1
∗∗
Gestation
72 2 .6 ±1.72 2 .1 ±1.9 20.7 ±
2.1
∗∗
20.4 ±
2.4
∗∗ 24.4 ±1.92 4 .3 ±2.92 2 .6 ±3.1 21.4 ±
2.1
∗∗
14 24.8 ±2.42 4 .2 ±2.22 3 .1 ±2.0
∗ 22.8 ±
2.3
∗∗ 26.3 ±2.22 6 .3 ±2.82 4 .7 ±2.6 23.7 ±
2.6
∗∗
20 26.0 ±2.42 5 .7 ±2.62 6 .0 ±2.22 5 .1±2.12 7 .7 ±2.12 6 .3 ±2.52 5 .8 ±2.12 6 .4±2.6
Lactation 21 68.4 ±8.56 8 .8 ±3.76 9 .4 ±4.06 7 .4±5.46 7 .2 ±6.66 7 .9 ±5.36 4 .1 ±6.46 5 .7±9.2
Mean ± standard deviation; signiﬁcantly diﬀerent from control: ∗P<. 05, ∗∗P<. 01; # the start of dosing for the F0 groups was at six weeks of age. The start
of dosing for the F1 group was on day 21 postparturition, to maintain SE5-OH ingestion via lactation; n: number of male and female rats per dose group.
published data by the USDA [30] indicate that daidzein,
genistein, and glycitein are constituents in a wide variety
of legumes, prepared foods, spices, teas, and of course, soy-
based foods, including infant formula, tofu, tempeh, cheese,
beverages, noodles, sauces, chips, and meat substitutes. In
unfermented food products, the glycosylated forms (i.e.,
daidzin, genistin, glycitin, and their derivatives) are more
abundantthantheaglyconeforms.Thewidespreadhistorical
exposure to soy isoﬂavones in the diet, without adverse
human health eﬀects, and the overall body of available
scientiﬁc evidence, is a compelling evidence of their safety.
While average Japanese isoﬂavone intake has been estimated
at 50mg/day, western consumption is approximated at
5mg/day[31, 32].Journal of Toxicology 7
Table 4: Organ weight changes in male and female breeding Sprague-Dawley rats in the F0 and F1 generations of the two-generation rat
study.
Generation F0 F1
Dose (mg/kg/day)
(n)
0( n = 26) 200 (n = 26) 1000 (n = 26) 2000 (n = 26) 0 (n = 22) 200 (n = 22) 1000 (n = 20) 2000 (n = 26)
Male
Thyroids, absolute
organ weight (mg)
A 30.01 ±5.45C 31.65 ±5.94 29.94 ±3.88 30.32 ±3.95 30.19 ±4.48 31.89 ±4.91 35.15 ±5.27
∗∗ 32.09 ±4.18
Thyroids, relative
organ weight (mg)
B 5.23 ±0.68 5.33 ±0.86 5.33 ± 0.73 5.34 ±0.78 4.55 ± 0.61 4.76 ±0.73 5.48 ±0.90
∗∗ 4.94 ±0.58
Adrenals, absolute
organ weight (mg)
61.81 ±7.05 63.95 ±10.16 59.48 ±7.40 68.90 ±9.01
∗∗ 62.18 ±7.30 63.96 ±5.83 57.61 ±7.52 62.28 ±9.25
Adrenals, relative
organ weight (mg)
10.88 ±1.31 10.82 ±1.68 10.57 ±1.28 12.10 ±1.58
∗∗ 9.41 ± 1.14 9.56 ±1.07 8.95 ±1.08 9.62 ±1.57
Seminal Vesicles,
absolute organ
weight (g)
3.11 ±0.33 2.90 ±0.37 3.12 ± 0.37 3.05 ±0.34 3.40 ± 0.29 3.26 ±0.44 3.23 ±0.39 3.13 ±0.37
Seminal vesicles,
relative organ weight
(g)
0.55 ±0.07 0.49 ±0.09
∗ 0.55 ± 0.08 0.54 ±0.06 0.52 ± 0.08 0.49 ±0.01 0.51 ±0.08 0.48 ±0.06
Generation F0 F1
Dose (mg/kg/day)
(n)
0( n = 26) 200 (n = 26) 1000 (n = 26) 2000 (n = 26) 0 (n = 18) 200 (n = 17) 1000 (n = 18) 2000 (n = 19)
Female
Liver, absolute organ
weight (g)
13.70 ±1.30 13.99 ±1.08 14.39 ±1.62 14.48 ±1.11 15.01 ±1.28 15.45 ±1.86 16.02 ±1.46 15.71 ±1.35
Liver, relative organ
weight (g)
3.86 ±0.32 4.05 ±0.31 4.17 ±0.35
∗∗ 4.23 ±0.29
∗∗ 4.12 ± 0.34 4.17 ±0.41 4.36 ±0.33 4.42 ±0.33
∗
Signiﬁcantly diﬀerent from control: ∗P<. 05, ∗∗P<. 01; Aabsolute organ weight is the weight of the organ; Brelative organ weight is the weight of the organ
r e l a t i v et ot h eb o d yw e i g h ta tn e c r o p s y( b o d yw e i g h tr a t i o ) ;Cmean± standard deviation; n: number of male and female rats per dose group.
Table 5: Eﬀect of SE5-OH administration on the reproductive performance of the F0 generation rat dams.
Dose
(mg/kg/day) Mean estrus cycle Incidence of
irregular estrus cycle
Mating period
Copulation index (%)
A Fertility index (%)
B
Number of estrus Day of conceiving
04 .26 ±0.43# 0.0 ±0.02 .5 ±1.8 100.0 96.2
(n = 25) 1/26 (n = 26) (n = 26) (26/26) (25/26)
200 4.18 ±0.32 0.0 ±0.02 .8 ±1.6 92.3 100.0
(n = 24) 2/26 (n = 26) (n = 24) (24/26) (24/24)
1000 4.21 ±0.40 0.0 ±0.02 .9 ±2.7 92.3 91.7
(n = 26) 0/26 (n = 26) (n = 24) (24/26) (22/24)
2000 4.15 ±0.38 0.0 ±0.03 .3 ±2.5 96.2 88.0
(n = 24) 2/26 (n = 26) (n = 25) (25/26) (22/25)
#Mean ± standard deviation; Anumber of copulated females/number of pairs; Bnumber of pregnant females/number of copulated females; n:n u m b e ro f
mating pairs.
Therehasbeenaconcernthatingestionofsoyisoﬂavones
may lead to adverse eﬀects on testes and ovaries [33–36].
Unlike diethylstilbestrol (DES), equol at 1000μg/animal/day
injected subcutaneously for ﬁve days failed to demonstrate
estrogenic, or antiestrogenic activity in the uterine wall of
neonatal Sprague-Dawley (SD) rats [37]. Other research
found that equol administration directly to the uterine horn
in ovariectomized rats did not increase uterine weight, and
although equol did weakly bind to the estrogen receptor with
ahighdissociationrate,itdidnotdemonstrateantiestrogenic
activity[38].InconcertwithﬁndingsreportedbyThompson
et al. [38], Wood et al. [39] found that high doses of
genistein and daidzein or equol had minimal uterotrophic
or mammotrophic eﬀects in an ovariectomized monkey
(Macaca fascicularis) model. In the normal postmenopausal
mammary gland of cynomolgus macaques, equol at an
equivalent human dose of 105mg/day for greater than six
months lacked estrogenic eﬀects, and did not promote
lesions in the mammary tissue [40]. Rachon et al. [41–
43] found that equol in the diet at 400mg per kg of food8 Journal of Toxicology
Table 6: Eﬀect of SE5-OH administration on the F1 generation rat dam reproductive performance.
Dose
(mg/kg/day) Mean estrus cycle Incidence of
irregular estrus cycle
Mating period
Copulation index (%)
A Fertility index (%)
B
Number of estrus Day of conceiving
04 .36 ±0.46# 0.1 ±0.63 .1 ±2.8 95.5 85.7
(n = 24) 0/24 (n = 22) (n = 21) (21/22) (18/21)
200 4.31 ±0.45 0.2 ±0.72 .8 ±1.8 95.7 86.4
(n = 21) 2/23 (n = 23) (n = 22) (22/23) (19/22)
1000 4.39 ±0.41 0.1 ±0.22 .3 ±1.3 100.0 95.0
(n = 20) 0/20 (n = 20) (n = 20) (20/20) (19/20)
2000 4.30 ±0.43 0.0 ±0.02 .5 ±1.5 100.0 95.5
(n = 21) 1/22 (n = 22) (n = 22) (22/22) (21/22)
#Mean ± standard deviation; Anumber of copulated females/number of pairs; Bnumber of pregnant females/number of copulated females; n:n u m b e ro f
mating pairs.
Table 7: Eﬀects of SE5-OH administration on F0 generation rat dam gestation and delivery parameters.
Dose
(mg/kg/day)
Gestation length
(days)
Number of
implantation sites
Number of oﬀspring
born alive Birth index
A (%) Gestation index
B (%)
02 2 .3 ±0.51 5 .0 ±3.91 3 .8 ±4.18 7 .12 ±21.64 96
n 24 25 25 25
200 22.2 ±0.41 5 .1 ±3.61 3 .8 ±3.48 9 .03 ±20.48 95.8
n 23 24 24 24
1000 22.3 ±0.61 5 .3 ±1.71 3 .6 ±3.38 9 .27 ±19.68 100.0
n 22 22 22 22
2000 22.0 ±0.31 4 .7 ±2.11 3 .8 ±2.39 3 .63 ±9.28 100.0
n 22 22 22 22
Signiﬁcantly diﬀerent from control: ∗P<. 05, ∗∗P<. 01; Abirth index = (number of oﬀspring born alive divided by the number of implantations); Bgestation
index = (number of females with live oﬀspring divided by the number of pregnant females); n:n u m b e ro fd a m sp e rg r o u p .
(delivering approx. 26.16mgequol/kg body weight/day to
the rat) for three months to ovariectomized rats signiﬁcantly
increased serum prolactin and lutenizing hormone levels
(P<. 05), but had no eﬀect on pituitary estrogen receptor
(ER)-αor-βgeneexpression.However,equoladministration
did increase an isoform of the estrogen receptor (Terp-1)
in the pituitary of these ovariectomized rats, and increased
the number of terminal ducts and type II lobules, compared
to control rats. Equol dosed at 3.68mg/kg/day in this same
study had no eﬀect on rat mammary tissue. In this same
ratmodel,equol(26.16mg/kgbodyweight/day)signiﬁcantly
increased uterine weights and increased the epithelial height
and thickness of the uterine stroma and myometrium,
and signiﬁcantly increased levels of uterine insulin-like
growth factor 1, progesterone receptor, and complement
protein 3mRNA, while 3.68mgequol/kg bodyweight/day
had no eﬀect [44]. Subcutaneous administration of up to
1000μg equol in rat pups during PND 1–5 or PND 10–14
lowered uterine weight at later ages, but did not aﬀect ER
levels [45]. Equol administration (approx. 27.48mg/kg body
weight/day) in ovariectomized rats for six weeks increased
uterine weight, decreased weight gain, and attenuated tra-
becular bone loss (but not proximal tibia bone loss), while
increasing its density, indicating mild bone sparing eﬀects
[46]. These studies indicate that there is an uncertain degree
of diﬀerence in species- and organ-speciﬁc sensitivity to
equol administration.
SE5-OH is a unique fermented soy germ food product
that is intended to deliver equol to individuals who cannot
produce it endogenously. The studies currently described
were conducted to determine any potential developmental
and reproductive eﬀects of SE5-OH. In the developmen-
tal study, isolated embryo-fetal eﬀects were noted dur-
ing necropsy, which included the fusion of placentae in
one dam in the 200mg/kg/day dose group. As no other
placental abnormalities were identiﬁed in this study, this
eﬀect was determined not to be test article-related. One
control group fetus and one high-dose fetus were found to
have a ventricular septal defect, and visceral variants that
included a thymic neck remnant, supernumerary coronary
ostium, left umbilical artery, and renal pelvis dilations which
occurred with equal incidence in these dose groups and
were determined not to be test article-related. Dumbell
ossiﬁcation of the thoracic centrum was signiﬁcantly lower
in the high-dose group, but the overall incidence of the
observed skeletal variants (as indicated in Table 4)w a s
determined not to be test article-related because they are
similarly seen in untreated Crl:CD(SD) rats.
An increase in relative (but not absolute) liver weight
was noted in the F0 1000 and 2000mg/kg/day dams, andJournal of Toxicology 9
Table 8: Eﬀects of SE5-OH administration on F1 generation rat dam gestation and delivery parameters.
Dose
(mg/kg/day)
Gestation length
(days)
Number of
implantation sites
Number of oﬀspring
born alive Birth index
A (%) Gestation index
B (%)
02 2 .2 ±0.41 5 .8 ±1.21 4 .9 ±1.99 3 .8 ±7.4 100
n = 18 n = 18 n = 18 n = 18
200 22.2 ±0.41 5 .8 ±2.51 4 .0 ±2.38 8 .9 ±9.2 100
n = 18 n = 18 n = 18 n = 18
1000 22.2 ±0.41 3 .8 ±4.11 2 .7 ±3.98 8 .1 ±22.8 94.7
n = 18 n = 19 n = 19 n = 19
2000 22.3 ±0.61 2 .6 ±4.7
∗ 11.3 ±5.18 4 .5 ±24.8 95.2
n = 20 n = 21 n = 21 n = 21
ABirth index = (number of oﬀspring born alive divided by the number of implantations); Bgestation index = (number of females with live oﬀspring divided
by the number of pregnant females); n:n u m b e ro fd a m sp e rg r o u p .
Table 9: Sperm parameters in control and high-dose male rats used as breeding males in the F0 and F1 two-generation reproduction study.
Dose
(mg/kg/day)
Sperm
motility (%)
HRS
(×106/g)
Sperm count (cauda
epididymal) (×106/g)
Abnormal
sperm (%)
Types of abnormal sperm (%) no. Tailless
sperm (%) ABCDE
F0 generation
09 1 .0 ±4.58 3 .73 ±12.52 534.73 ±72.79 0.81 ±1.26 0.25 ±
0.62
0.04 ±
0.14
0.00 ±
0.00
0.42 ±
0.76
0.10 ±
0.40 1.96 ±2.03
n 26 26 26 26 26 26 26 26 26 26
2000 91.3 ±3.28 3 .64 ±10.21 537.29 ±66.92 0.33 ±0.37 0.04 ±
0.14
0.00 ±
0.00
0.00 ±
0.00
0.29 ±
0.35
0.00 ±
0.00 1.81 ±2.83
n 26 26 26 26 26 26 26 26 26 26
F1 generation
08 6 .0 ±20.17 5 .98 ±17.86 551.21 ±151.94 0.52 ±0.83 0.31 ±
0.43
0.00 ±
0.00
0.00 ±
0.00
0.21 ±
0.62
0.00 ±
0.00 1.95 ±1.77
n 22 22 22 21 21 21 21 21 21 21
2000 86.7 ±19.78 1 .57 ±14.31 557.51 ±142.72 0.40 ±0.71 0.19 ±
0.51
0.00 ±
0.00
0.00 ±
0.00
0.21 ±
0.34
0.00 ±
0.00 5.18 ±15.30
n 22 22 22 22 22 22 22 22 22 22
A: without hook, B: banana-like head, C: amorphous, D: folded in midpiece, E: others; HRS: homogenization-resistant spermatids; n:n u m b e ro fm a l e sp e r
group.
in the 2000mg/kg/day F1 dams, but was not seen in the
male rats. The increase at the 1000mg/kg/day dose did
not exceed the limits of 5% variability, which is generally
considered within the accepted level of variability to the
control rats. The relative liver weight at the 2000mg/kg/day
dose had greater than 5% variability from controls. There
was a signiﬁcant increase in the absolute and relative thyroid
weight in the 1000mg/kg/day dose group, but this was not
considered related to SE5-OH treatment, as this eﬀect was
not noted in any other dose levels. The highest dose of SE5-
OH (2000mg/kg/day) had some indications of toxicity at the
gestational and conception stages in the rat model.
The adrenal cortex of F0 females at the 2000mg/kg/day
SE5-OH dose had an increased number of diﬀuse lipid
droplets (4/10 in the high-dose group versus 0/10 in the
controls) noted in the glomerular zone of the adrenal glands.
Lipiddropletsaretheintracellularstoresofcholesterolesters,
precursors of hormones formed in the rat adrenal glands
[47]. It has been documented that cell enlargement and
widening of the zona glomerulosa of the adrenal cortex
(associated with an increase in lipid droplet volume) may be
induced via androgen receptor binding, and that isoﬂavones
(including equol as an antiandrogen [48]) have been
reported to alter androgen receptor expression and adreno-
cortical function [49, 50]. However, the exact mechanism is
not known, as isoﬂavones have been shown to increase or
decreaseandrogenproduction,dependingonthemodelused
[51–54]. Wood et al. [53] noted that consumption of a soy
protein providing 129mg/day isoﬂavones (which provided
approx. 31mg daidzein per day) by female cynomolgus
monkeys for 36 months did not alter serum androgen
levels, but decreased adrenal weight (P<. 0006). However,
previous postmenopausal oral contraceptive administration
abolished this eﬀect (P<. 01). Diﬀuse lipid droplets in
the adrenal cortex have been noted in the rat model as
a consequence of advancing age [47], and coupled with
pregnancy, they may have been a factor in the results of
this study. The maximal plasma concentration was 390 ±
90 and 414 ± 32ng/mL, respectively, for the S- and R-
enantiomers.10 Journal of Toxicology
Table 10: Litter size and viability index of the F1 generation rat pups exposed to SE5-OH during gestation and through lactation of the F0
dams.
Dose (mg/kg/day)
0 n 200 n 1000 n 2000 n
Number of total oﬀspring at birth
Males #7.6 ±2.72 4 7 .3 ±2.52 37 .4 ±2.02 2 6 .7 ±1.92 2
Females 7.0 ±2.02 47 .3 ±2.62 36 .5 ±1.72 2 7 .1 ±2.32 2
Total 14.6 ±2.82 41 4 .7 ±1.92 31 4 .2 ±1.82 2 1 3 .8 ±2.32 2
(M/F) (183/168) (169/169) (162/144) (147/157)
Number of live oﬀspring at birth
Males 7.5 ±2.82 47 .3 ±2.62 37 .2 ±2.32 2 6 .6 ±2.02 2
Females 6.9 ±2.02 47 .2 ±2.42 36 .4 ±2.22 2 7 .1 ±2.32 2
Total 14.4 ±3.02 41 4 .4 ±1.62 31 3 .6 ±3.32 2 1 3 .8 ±2.32 2
(M/F) (179/166) (167/165) (159/140) (146/157)
Number of live oﬀspring on PND 4 before culling
Males 7.4 ±2.82 47 .2 ±2.62 37 .1 ±2.42 2 6 .5 ±1.82 2
Females 6.7 ±2.02 47 .1 ±2.32 36 .2 ±2.12 2 7 .0 ±2.32 2
Total 14.1 ±2.92 41 4 .3 ±1.62 31 3 .3 ±3.52 2 1 3 .5 ±2.22 2
(M/F) (178/160) (166/164) (156/137) (144/154)
Number of live oﬀspring on PND 4 after culling
Males 3.9 ±0.92 44 .0 ±0.22 34 .0 ±0.22 1 4 .0 ±0.22 2
Females 3.9 ±0.42 44 .0 ±0.22 34 .0 ±0.22 1 4 .0 ±0.32 2
Total 7.8 ±1.22 48 .0 ±0.02 38 .0 ±0.02 1 8 .0 ±0.22 2
Number of live oﬀspring on PND 21
Males 3.9 ±0.92 44 .0 ±0.22 34 .0 ±0.42 1 3 .9 ±0.32 2
Females 3.9 ±0.42 44 .0 ±0.22 34 .0 ±0.22 1 3 .9 ±0.42 2
Total 7.8 ±1.22 48 .0 ±0.02 37 .9 ±0.32 1 7 .8 ±0.52 2
Viability index
A (%)
PND 0 96.86 ±10.27 24 98.50 ±4.99 23 95.78 ±19.81 22 99.62 ±1.77 22
PND 4 98.23 ±3.70 24 99.42 ±1.92 23 93.75 ±21.38 22 98.58 ±4.28 22
PND 21 100.00 ±0.00 24 100.00 ±0.00 23 98.81 ±3.76 21 98.30 ±5.84 22
#Mean ± standard deviation; n: number of litters; PND: postnatal day; Aviability index: PND 0: (number of live oﬀspring born alive/number of oﬀspring
born), PND 4: (number of oﬀspring alive on PND 4/number of oﬀspring born alive), PND 21: (number of live weanlings/number of live oﬀspring after
culling).
Although a signiﬁcant reduction in the number of
implantations in this study is thought to have occurred
due to lowered caloric intake in the high-dose pregnant
dams, it still remains that there was an overall adverse eﬀect,
albeit an indirect one (i.e., an eﬀect of reduced caloric
intake on decreased body weights) and not a product of
the intrinsic toxicity of SE5-OH on the reproductive ability
of the rats in this study. Even though a transient decrease
in body weight gain was noted in F0 and F1 dams of the
2000mg/kg/day dose group, no changes were observed in
fetal viability, intrauterine growth, and fetal morphology
(external, skeletal, and visceral) that were attributed to
SE5-OH treatment. Isolated embryo-fetal alterations were
noted, but were not consistent with SE5-OH treatment or
signiﬁcantly diﬀerent from controls. It is known that food
restriction aﬀects the adult female rat reproductive capacity
and may decrease the number of corpus luteum graviditatis
[55, 56]. Equol administration to ovariectomized rats at
approximately 27.48mg/kg/day for six weeks [44]r e s u l t e d
in decreased weight gain, intra-abdominal fat, plasma leptin,
and total cholesterol levels. Soy isoﬂavone administration
to male, female, and ovariectomized rats reduced food
intake and weekly body weight gain, while increasing
serum isoﬂavones, including equol [57]. A decrease in
implantations was noted at the 2000mg/kg/day dose group;
however, since no adverse eﬀe c t sw e r en o t e do no r g a n
weightsorhistopathologicalexaminationofthereproductive
organs, mating ability, fertility, pregnancy, parturition, or
nursing behavior in F0 or F1 animals, this slight decrease in
implantation number was not a substantive or meaningful
eﬀect. Further, the absence of an eﬀect on the fecun-
dity of the high-dose animals in the reproduction study
indicates this decrease in implantation was an anomalous
ﬁnding, and is supported by the lack of reproductive
toxicity by daidzein in rats reported by Lamartiniere et al.
[34]. In a previous work [26], no adverse observations
were found in adult rats at up to 2000mg/kg/day SE5-
OH in a subchronic 90-day study. In the present study,
no adverse toxicological observations were made at either
the reproductive or developmental stages in the either sexJournal of Toxicology 11
Table 11: Litter size and viability index of the F2 generation rat pups exposed to SE5-OH during gestation through lactation.
Dose (mg/kg/day)
0 n 200 n 1000 n 2000 n
Number of total oﬀspring at birth
Males #8.0 ±2.81 8 7 .9 ±2.51 86 .9 ±1.81 86 .9 ±2.92 0
Females 7.0 ±2.41 8 6 .6 ±2.71 86 .6 ±2.21 85 .5 ±2.72 0
Total 15.0 ±1.91 8 1 4 .4 ±2.21 81 3 .5 ±2.51 81 2 .4 ±4.22 0
(M/F) (144/126) (142/118) (124/119) (137/109)
Number of live oﬀspring at birth
Males 8.0 ±2.81 8 7 .6 ±2.61 86 .9 ±1.81 86 .6 ±3.02 0
Females 6.9 ±2.31 8 6 .4 ±2.51 86 .6 ±2.31 85 .4 ±2.82 0
Total 14.9 ±1.91 8 1 4 .0 ±2.31 81 3 .4 ±2.51 81 1 .9 ±4.52 0
(M/F) (144/124) (137/115) (124/118) (131/107)
Number of live oﬀspring on PND 4 before culling
Males 7.8 ±2.71 8 7 .2 ±3.11 86 .4 ±2.11 86 .4 ±3.21 9
Females 6.8 ±2.31 8 6 .9 ±3.01 86 .3 ±2.11 85 .2 ±3.01 9
Total 14.6 ±1.81 8 1 3 .2 ±4.01 81 2 .7 ±2.71 81 1 .5 ±5.01 9
(M/F) (140/122) (130/107) (115/113) (127/103)
Number of live oﬀspring on PND 4 after culling
Males 3.9 ±0.61 8 4 .2 ±0.71 73 .9 ±0.51 83 .9 ±1.01 9
Females 4.1 ±0.61 8 3 .8 ±0.71 74 .0 ±0.61 8 3 .4
∗ ±1.01 9
Total 8.0 ±0.01 8 8 .0 ±0.01 77 .9 ±0.21 8 7 .4
∗ ±1.31 9
Number of live oﬀspring on PND 21
Males 3.8 ±0.61 8 4 .2 ±0.71 73 .8 ±0.61 83 .9 ±1.01 9
Females 4.1 ±0.51 8 3 .7 ±0.81 74 .0 ±0.61 83 .4 ±1.01 9
Total 7.9 ±0.31 8 7 .9 ±0.21 77 .8 ±0.51 87 .4 ±1.31 9
Viability index
A (%)
PND 0 99.23 ±2.23 18 96.92 ±4.89 18 99.54 ±1.96 18 96.21 ±12.29 20
PND 4 97.91 ±4.15 18 93.61 ±23.49 18 94.65 ±12.02 18 94.43 ±22.30 19
PND 21 98.61 ±4.04 18 99.26 ±3.03 17 98.51 ±4.34 18 100.00 ±0.00 19
#Mean ± standard deviation; n = number of litters; PND: postnatal day; Aviability index: PND 0: (number of live oﬀspring born alive/number of oﬀspring
born), PND 4: (number of oﬀspring alive on PND 4/number of oﬀspring born alive), PND 21: (number of live weanlings/number of live oﬀspring after
culling).
of the rat model at the 1000mg/kg/day dose. From the
combined studies herein, we can conclude that in the
developmental toxicity phase of the study, a no-observed-
adverse-eﬀect-level (NOAEL) for developmental eﬀects of
SE5-OH is 2000mg/kg/day, based on the lack of signiﬁcant
embryo-to-fetal stage eﬀect. From the reproductive study,
the NOAEL for SE5-OH determined for both male and
female rats is 1000mg/kg/day (6.5mgequol/kg/day), based
on the reduction of body weight, implantations, and live
births in the F1 and F2 animals at the 2000mg/kg/day dose
level.
Nomenclature
ANOVA: Analysis of variance
DES: Diethylstilbestrol
ER: Estrogen receptor
GLP: Good laboratory practice
HPMC: Hydroxypropylmethylcellulose
MHW: Ministry of Health and Welfare (Japan)
NOAEL: No-observed-adverse-eﬀect-level.
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